Cargando…
A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia
Erythropoiesis-stimulating agents improve the NYHA functional class and decrease the hospital readmission rates for heart failure; however, little is known about the influence of continuous erythropoietin receptor activator (CERA) on the heart. Therefore, a prospective study was conducted to investi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046271/ https://www.ncbi.nlm.nih.gov/pubmed/36979925 http://dx.doi.org/10.3390/biomedicines11030946 |
_version_ | 1785013631291752448 |
---|---|
author | Sezai, Akira Sekino, Hisakuni Taoka, Makoto Osaka, Shunji Tanaka, Masashi |
author_facet | Sezai, Akira Sekino, Hisakuni Taoka, Makoto Osaka, Shunji Tanaka, Masashi |
author_sort | Sezai, Akira |
collection | PubMed |
description | Erythropoiesis-stimulating agents improve the NYHA functional class and decrease the hospital readmission rates for heart failure; however, little is known about the influence of continuous erythropoietin receptor activator (CERA) on the heart. Therefore, a prospective study was conducted to investigate the effects of CERA on cardiac and renal function and oxidative stress in chronic heart failure with renal anemia. Sixty patients with chronic heart failure and renal anemia were enrolled and received CERA for 12 months. The primary endpoints were hemoglobin (Hb) and hematocrit, and the secondary endpoints were: (1) atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP); (2) NYHA class; (3) echocardiography; (4) blood urea nitrogen, creatinine, cystatin C, and urinary albumin; (5) high-sensitivity C-reactive protein; (6) oxidized low-density lipoprotein (Ox-LDL); and (7) renin, angiotensin-II, and aldosterone. There was a significant difference in the Hb levels measured before and after CERA administration. The BNP, ANP, NYHA, left ventricular mass index, renal function, and Ox-LDL decreased significantly after CERA administration. This study shows that CERA improves anemia and reduces renal impairment, as well as cardiac and oxidative stress. The result of this study is useful for a study in which switching from CERA to a new renal anemia drug, hypoxia-inducible factor prolyl-hydroxylase inhibitor, is investigated. |
format | Online Article Text |
id | pubmed-10046271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100462712023-03-29 A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia Sezai, Akira Sekino, Hisakuni Taoka, Makoto Osaka, Shunji Tanaka, Masashi Biomedicines Article Erythropoiesis-stimulating agents improve the NYHA functional class and decrease the hospital readmission rates for heart failure; however, little is known about the influence of continuous erythropoietin receptor activator (CERA) on the heart. Therefore, a prospective study was conducted to investigate the effects of CERA on cardiac and renal function and oxidative stress in chronic heart failure with renal anemia. Sixty patients with chronic heart failure and renal anemia were enrolled and received CERA for 12 months. The primary endpoints were hemoglobin (Hb) and hematocrit, and the secondary endpoints were: (1) atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP); (2) NYHA class; (3) echocardiography; (4) blood urea nitrogen, creatinine, cystatin C, and urinary albumin; (5) high-sensitivity C-reactive protein; (6) oxidized low-density lipoprotein (Ox-LDL); and (7) renin, angiotensin-II, and aldosterone. There was a significant difference in the Hb levels measured before and after CERA administration. The BNP, ANP, NYHA, left ventricular mass index, renal function, and Ox-LDL decreased significantly after CERA administration. This study shows that CERA improves anemia and reduces renal impairment, as well as cardiac and oxidative stress. The result of this study is useful for a study in which switching from CERA to a new renal anemia drug, hypoxia-inducible factor prolyl-hydroxylase inhibitor, is investigated. MDPI 2023-03-20 /pmc/articles/PMC10046271/ /pubmed/36979925 http://dx.doi.org/10.3390/biomedicines11030946 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sezai, Akira Sekino, Hisakuni Taoka, Makoto Osaka, Shunji Tanaka, Masashi A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title | A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title_full | A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title_fullStr | A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title_full_unstemmed | A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title_short | A Single Arm Clinical Study on the Effects of Continuous Erythropoietin Receptor Activator Treatment in Non-Dialysis Patients with Chronic Heart Failure and Renal Anemia |
title_sort | single arm clinical study on the effects of continuous erythropoietin receptor activator treatment in non-dialysis patients with chronic heart failure and renal anemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046271/ https://www.ncbi.nlm.nih.gov/pubmed/36979925 http://dx.doi.org/10.3390/biomedicines11030946 |
work_keys_str_mv | AT sezaiakira asinglearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT sekinohisakuni asinglearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT taokamakoto asinglearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT osakashunji asinglearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT tanakamasashi asinglearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT sezaiakira singlearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT sekinohisakuni singlearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT taokamakoto singlearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT osakashunji singlearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia AT tanakamasashi singlearmclinicalstudyontheeffectsofcontinuouserythropoietinreceptoractivatortreatmentinnondialysispatientswithchronicheartfailureandrenalanemia |